Actively Recruiting
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Led by AstraZeneca · Updated on 2026-05-05
695
Participants Needed
32
Research Sites
276 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.
CONDITIONS
Official Title
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eastern Cooperative Oncology Group performance status (ECOG PS) with no worsening in the past 2 weeks
- Progressive cancer at enrollment
- Adequate organ and marrow function
- Specific gene mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D depending on module
- Evaluable disease measurable by imaging
- Suitable for treatment with PARP inhibitors or temozolomide as applicable
- Ability to eat high fat meal and follow fasting restrictions
- Female participants of childbearing potential must have negative pregnancy tests and use effective contraception
- Male participants must use condoms with spermicide and avoid fathering a child during and for months after treatment
- Provided tumor samples for testing as required
- ECOG performance status of 0 or 1
- Consent to tumor biopsies for pharmacodynamics evaluation if applicable
You will not qualify if you...
- Major surgery within 4 weeks before first treatment dose
- Recent radiotherapy within 2 to 4 weeks before treatment
- Unresolved toxicities from prior therapy above grade 1 except alopecia
- Severe or uncontrolled systemic diseases including infections with hepatitis B, C, or HIV
- Uncontrolled seizures or history of severe brain injury or stroke
- Myelodysplastic syndrome or acute myeloid leukemia
- Significant gastrointestinal conditions affecting drug absorption
- Allergy to study drugs or excipients
- Contraindications to MRI or unstable corticosteroid use before baseline MRI
- Concurrent anti-cancer therapies or prohibited medications
- Previous extensive therapy with PARP inhibitors or alkylating chemotherapy as specified per module
- Certain blood clotting or neurological conditions
- BMI over 30 kg/m2 or body weight over 100 kg for PET sub-study
- Use of immunosuppressive medication or corticosteroids above certain doses before treatment
- History of other primary malignancies or severe lung diseases
- Pregnant or breastfeeding participants or those planning pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 32 locations
1
Research Site
La Jolla, California, United States, 92093
Withdrawn
2
Research Site
Los Angeles, California, United States, 90095
Actively Recruiting
3
Research Site
San Francisco, California, United States, 94143
Actively Recruiting
4
Research Site
Chicago, Illinois, United States, 60611
Actively Recruiting
5
Research Site
Boston, Massachusetts, United States, 02215
Actively Recruiting
6
Research Site
New York, New York, United States, 10040
Actively Recruiting
7
Research Site
New York, New York, United States, 10065
Actively Recruiting
8
Research Site
Portland, Oregon, United States, 97239
Completed
9
Research Site
Houston, Texas, United States, 77030
Actively Recruiting
10
Research Site
San Antonio, Texas, United States, 78229
Not Yet Recruiting
11
Research Site
Richmond, Virginia, United States, 23298
Withdrawn
12
Research Site
Darlinghurst, Australia, 2010
Actively Recruiting
13
Research Site
Melbourne, Australia, 3000
Actively Recruiting
14
Research Site
Randwick, Australia, 2031
Actively Recruiting
15
Research Site
Bayern, Germany, 80337
Withdrawn
16
Research Site
Berlin, Germany, 13353
Withdrawn
17
Research Site
Heidelberg, Germany, 69120
Withdrawn
18
Research Site
Mainz, Germany, 55131
Withdrawn
19
Research Site
Seoul, South Korea, 03080
Actively Recruiting
20
Research Site
Seoul, South Korea, 03722
Actively Recruiting
21
Research Site
Seoul, South Korea, 06351
Actively Recruiting
22
Research Site
A Coruña, Spain, 15006
Actively Recruiting
23
Research Site
Barcelona, Spain, 8035
Actively Recruiting
24
Research Site
Málaga, Spain, 29010
Actively Recruiting
25
Research Site
Pozuelo de Alarcón, Spain, 28223
Actively Recruiting
26
Research Site
Sant Cugat del Vallès, Spain, 08195
Actively Recruiting
27
Research Site
Seville, Spain, 41013
Actively Recruiting
28
Research Site
Lund, Sweden, 22185
Actively Recruiting
29
Research Site
Stockholm, Sweden, 118 83
Actively Recruiting
30
Research Site
Glasgow, Scotland, United Kingdom, G12 0YN
Actively Recruiting
31
Research Site
London, United Kingdom, EC1M 6BQ
Actively Recruiting
32
Research Site
Newcastle upon Tyne, United Kingdom, NE7 7DN
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
A
AstraZeneca Breast Cancer Study Locator Service
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
9
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here